AU2003229976B2 - Production of crystalline materials by using high intensity ultrasound - Google Patents
Production of crystalline materials by using high intensity ultrasound Download PDFInfo
- Publication number
- AU2003229976B2 AU2003229976B2 AU2003229976A AU2003229976A AU2003229976B2 AU 2003229976 B2 AU2003229976 B2 AU 2003229976B2 AU 2003229976 A AU2003229976 A AU 2003229976A AU 2003229976 A AU2003229976 A AU 2003229976A AU 2003229976 B2 AU2003229976 B2 AU 2003229976B2
- Authority
- AU
- Australia
- Prior art keywords
- ultrasound
- solution
- vessel
- transducers
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 42
- 239000002178 crystalline material Substances 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 19
- 108010011485 Aspartame Proteins 0.000 claims abstract description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 7
- 239000000605 aspartame Substances 0.000 claims abstract description 7
- 229960003438 aspartame Drugs 0.000 claims abstract description 7
- 235000010357 aspartame Nutrition 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 abstract description 29
- 239000012047 saturated solution Substances 0.000 abstract description 11
- 230000003628 erosive effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 2
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 description 37
- 238000002425 crystallisation Methods 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019454 L-leucine Nutrition 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- -1 aspartic acid Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
- C07K5/0613—Aspartame
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
- B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0036—Crystallisation on to a bed of product crystals; Seeding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0063—Control or regulation
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Thermal Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
A crystalline material sufficiently pure for use in pharmaceuticals may be made by forming a saturated solution of the material, changing the temperature of the solution so it becomes supersaturated, and briefly subjecting the solution to irradiation by high intensity ultrasound, before allowing the solution to cool gradually without further irradiation. The ultrasound may be applied using a vessel with an array of ultrasonic transducers attached to a wall, so each transducer radiates no more than 3 W/cm<2> yet the power dissipation within the vessel is between 25 and 150 W/litre. This method can reduce the metastable zone width to less than 10 K. There is no erosion of the wall and consequently no formation of small particles of metal. It is applicable for example to aspartame, and to amino acids.
Description
WO 03/101577 PCT/GB03/01905 1 PRODUCTION OF CRYSTALLINE MATERIALS BY USING HIGH INTENSITY ULTRASOUND.
This invention relates to a method for crystallisation of ingredients that may be suitable for use in pharmaceuticals.
The use of high intensity ultrasound to trigger nucleation in a supersaturated solution, so that crystallisation occurs, is known, and an apparatus for this purpose is for example described in GB 2 276 567 A.
The benefits of triggering nucleation in this fashion are of particular relevance when very pure crystalline products are to be formed, as the purity of the solution and the cleanliness of the vessel surfaces means that crystallisation nuclei are not otherwise present.
Certain compounds would be desirable for use in pharmaceuticals, but have been found particularly difficult to crystallise; this relates in particular to disaccharides such as D-glucose or D-xylose. Similar problems arise with other organic compounds such as aspartic acid, and the compound a-L-aspartyl-Lphenylalanine methyl ester (aspartame). It has often been found necessary to add crystal modifiers to a saturated solution of such compounds to encourage the formation of crystals, as a saturated solution may have to be cooled considerably below the saturation temperature before crystallisation occurs; with some organic materials this under-cooling may be as much as 100 K. That is to say, a supersaturated solution may remain in a metastable state for a prolonged period, which may be many months. The use of an immersed ultrasonic probe or horn to subject a saturated solution to ultrasound is commonly used, but it has been found that some cavitation occurs at the surface of the horn, this causing erosion of the horn and consequential generation of very small metal particles (say about 0.1 mm in diameter); consequently this process WO 03/101577 PCT/GB03/01905 2 would not be acceptable for generating crystalline material for use as a pharmaceutical ingredient.
Accordingly the present invention provides a method for production of crystalline material, the method comprising forming a saturated solution of the material, changing the temperature of the solution so it becomes supersaturated, and subjecting the solution to irradiation by high intensity ultrasound, the ultrasound being applied only while the solution is supersaturated, and being applied only until crystals are formed, and then allowing the crystals in the solution to grow without irradiation.
Preferably the ultrasound is applied for a time no more than 10 seconds, for example 2 seconds or 3 seconds.
The ultrasound most preferably is applied for a brief interval of say less than 5 seconds, and then the solution inspected to see if any crystals have been formed; if no crystals have been formed than the ultrasound may again be applied for a brief interval, and the solution again inspected. This may be repeated until crystals appear, after which ultrasound is no longer applied. Further gradual cooling of the solution, subsequent to the application of ultrasound, will lead to growth of the crystals formed during the ultrasonic insonation. Hence this method enables large crystals to be grown.
The ultrasound may be applied to the supersaturated solution in a vessel using a multiplicity of ultrasonic transducers attached to a wall of the vessel in an array extending both circumferentially and longitudinally, each transducer being connected to a signal generator so that 2 the transducer radiates no more than 3 W/cm the transducers being sufficiently close together and the WO 03/101577 PCT/GB03/01905 3 number of transducers being sufficiently high that the power dissipation within the vessel is between 25 and 150 W/litre. The values of power given here are those of the electrical power delivered to the transducers, as this is relatively easy to determine. Such an irradiation vessel is described in WO 00/35579. Surprisingly it has been found that with such a vessel there is no cavitation at the surface of the wall, so that there is no erosion of the wall and consequently no formation of small particles of metal. The crystalline material made by this method can.be very pure, as additives are not required and the crystallisation procedure does not introduce contaminants, so that it would be suitable both for food use and for pharmaceutical use.
It is desirable to ensure no focusing of the ultrasound occurs, and this may be achieved by energising groups of adjacent transducers in succession. Where the vessel is cylindrical it is particularly preferable to avoid energising diametrically opposite transducers at the same time. The non-focusing can also be achieved by energising adjacent transducers, or adjacent groups of transducers, at different frequencies; and in particular to vary the frequency at which each transducer. or group of transducers is energized over a limited range, for example between 19.5 kHz and 20.5 kHz.
The invention will now be further and more particularly described, by way of example only, and with reference to the accompanying drawing which shows a cross-sectional view of a batch crystallisation irradiator.
Referring to the drawing, a batch crystallisation irradiator 10 includes a stainless-steel vessel 12 of internal diameter 0.31 m and of wall thickness 2 mm. To WO 03/101577 PCT/GB03/01905 4 the outside of the wall are attached sixty transducer modules 14 closely packed in a square array. Each transducer module 14 comprises a 50 W piezoelectric transducer 16 which resonates at 20 kHz, attached to a conically flared titanium coupling block 18 by which it is connected to the wall, the wider end of each block being of diameter 63 mm. The transducer modules define five circumferential rings each of twelve modules 14, the centres of the coupling blocks 18 being on a square pitch of 82 mm. The irradiator 10 also incorporates three signal generators 20 (only one is shown) each of which drives the transducers 16 in a pair of adjacent longitudinal rows and another such pair of rows one third of the circumference apart from the first pair.
In use of the irradiator 10 the vessel 12 is filled with a solution and the temperature of the vessel is gradually lowered (assuming the solubility decreases as the temperature decreases) using a cooling jacket 22, and the contents of the vessel 12 are stirred. Consequently the solution will become saturated and then supersaturated. When the temperature is about 10 K below that at which saturation occurs, the transducers are energized briefly, each generator 20 being energized for 0.8 second successively. Each transducer irradiates 50 W over a circle of diameter 63 mm, that is an intensity of 1.6 W/cm 2 The ultrasonic energy is dissipated over the cylindrical volume of the vessel 12, which is about 31 litres, so if all the transducers 16 were energised simultaneously the power density would be about 100 W/litre. To avoid focusing, only one signal generator is energized at any one time, so the energy deposition is about 33 W/litre. After 0.8 second, a different generator 20 is energized, and so on. After 2.4 seconds each transducer has been energized, and application of ultrasound is terminated. The contents of the vessel 12 WO 03/101577 PCT/GB03/01905 5 are then inspected, to see if any crystals have formed.
If there are no crystals this activation procedure is repeated. Once crystals are observed, application of ultrasound is terminated, and the temperature of the vessel 12 is gradually lowered.
In a modification the signal generators 20 may generate signals at a frequency that varies between 19.5 and 20.5 kHz, the signals f:.om different signal generators 20 varying independently of each other.
With this irradiator 10 the power intensity is such that cavitation does not occur at the surface of the wall, so erosion of the vessel 12 does not occur.
Nevertheless the power density is sufficient to ensure nucleation in a saturated solution.
An experiment to investigate the effect of ultrasound on crystallisation has been performed, as follows. An aqueous solution of D-xylose containing 25 g D-xylose per 10 ml water was prepared, which would be saturated at 50 0 C. This was than cooled at a rate of 0.2 K/min to 20°C, and the resulting solid products were separated and isolated. As a control, in one case the transducers 14 were not energized; in this case crystals did not appear until the temperature had dropped to 36°C.
If the transducers 14 were energized for a period of 2 minutes, starting at 46°C, then crystals appeared at 43°C. If the transducers 14 were energized continuously, starting at 50 0 C, then the resulting crystals were very small, and information on sizes was not obtained. Table 1 gives the temperature T at which solid first appeared and also shows the effect on crystal size distribution by indicating the crystal size (in aLm) for different cumulative percentiles (by mass): WO 03/101577 PCT/GB03/01905 6 Table 1 Conditions T/°C 10% 50% No ultrasound 36 27 67 149 2 min ultrasound 43 43 106 211 Ultrasound 46 Since the solutions were saturated at 50°C, ideally crystallisation should commence as soon as the temperature drops below 50 0 C. The short application of ultrasound markedly reduces the metastable zone width to only about 7 K (as compared to about 14 K in the absence of ultrasound). It also gives a significant increase in the crystal sizes that are formed. Continuous application of ultrasound reduces the metastable zone width even more, to about 4 K.
It will be appreciated-that the conditions that applied in this particular experiment do not exactly correspond to the method of the present invention, but tnat the results indicate that it would be appropriate to cool the solution to about 43°C before subjecting it to brief irradiation.
In performing the present invention, the temperature to which the solution is to be cooled before the brief application of ultrasound will differ for different solutions, depending on the material, the solvent and the concentration, and must therefore be found by experiment.
It may be ascertained by experiments similar to those described above. The solution is first subjected to continuous ultrasound as it is cooled, and the temperature at which crystals form which in the example above was 46 0 C) is observed. Further tests are then carried out, cooling the solution to different WO 03/101577 PCT/GB03/01905 -7 temperatures within a few degrees above or below T to find the highest temperature at which crystals form on application of a brief pulse of ultrasound. Typically this is within 5 K of the temperature T observed with continuous ultrasound.
Aspartame is the a-dipeptide ester L-aspartyl-Lphenylalanine methyl ester and is an important synthetic low-calorie sweetening agent. It is about 200 times sweeter than sugar and does not leave a bitter aftertaste, and so is used in a wide range of products.
It is, however, difficult to crystallise without use of crystal modifiers, particularly from aqueous solution.
Surprisingly, it has been found possible to produce satisfactory crystals of aspartame directly from an aqueous solution using the present method. A saturated solution of aspartame in warm pure water is prepared, and introduced into the vessel 12. The temperature of the solution is gradually cooled to about 10 K below the temperature at which it would be saturated, and is subjected to ultrasonic irradiation as described above for a short time, for example 2.4 s. The solution is then inspected, and if crystals have formed as a result of the ultrasonic irradiation, then the temperature of Lhe vessel is gradually cooled over a period of a few hours down to room temperature.
This process has been found to produce aspartame crystals between 100 and 250 nim in size, which are easy to separate from the remaining liquid for example by filtration. By avoiding the need for additives the purity of the product is ensured.
The inspection to check if any crystals have formed as a result of the ultrasonic irradiation may be an inspection by eye, while shining a light into the WO 03/101577 PCT/GB03/01905 8 solution, as the small crystals sparkle.
It will be appreciated that the method is applicable using different apparatus, and may be applied on a continuous rather than a batch basis. For example a saturated solution may be c.used to flow along a duct in which its temperature gradually decreases, the duct incorporazing a flow-through ultrasonic irradiation module at a position at which the solution has reached the appropriate temperature, so that the solution is briefly irradiated as it flows through the module. In this case the transducers of the ultrasonic irradiation module might be activated continuously or in a pulsed mode.
The method is applicable to many different chemical compounds. For example it may be used for proteins and amino acids, and for antibiotics. By way of example, the following measurements have been made with the three amino acids L-leucine, L-phenylalanine, and L-histadine.
Saturated solutions in water were prepared at 75 0
C,
the concentrations being 3.3, 6.2 and 11.3 g/100 g water respectively (after 24 hours in contact with solid material). Four samples were taken of each solution, and were then cooled at a steady rate of 0.2 0 C/min. In half the cases the samples were subjected to a 10 s burst of ultrasound every 5 minutes until crystals were observed.
No ultrasound was applied to the others. The temperature, T, at which crystals first appeared is shown in Table 2, Tu being the cases with ultrasound, and Tx those without ultrasound.
WO 03/101577 PCT/GB03/01905 9- TABLE 2 Tx/oC Tx/OC Tu/OC Tu/°C L-leucine 52.9 52.2 66.0 64.5 L-phenylalinine 65.2 66.4 69.1 71.0 L-histadine 65.5 67.0 69.0 70.1 It will be appreciated that in each case the application of ultrasound reduces the metastable zone width, so the crystals appear at a higher temperature.
The effect is most dramatic in the case of leucine, where the metastable zone is decreased from about 22.5 K to about 9.8 K. In addition, the ultrasound has an effect on the crystal size distribution, so that the crystals are larger. For example Table 3 shows measurements of the resulting crystal size distributions, as measured with a Malvern Mastersizer 2000, for histadine and phenylalanine, showing the particle sizes (in pm) for different cumulative percentiles (by mass).
TABLE 3 10% 50% Histadine no ultrasound 15.8 59.9 166.3 Histadine ultrasound 20.6 89.6 370.8 Phenylalanine no ultrasound 133.9 352.4 655.9 Phenylalanine ultrasound 159.9 420.9 776.1 As another application, a saturated solution may be insonated so as to generate crystals, and then be added to a larger volume of solution so that the crystals act as seed crystals for the entire volume. For example there might be 4000 litres of a saturated solution in a crystallisation tank, which is gradually cooled or to which anti-solvent is added. When it is sufficiently supersaturated, a small quantity (eg 40 1) is transferred into an irradiation chamber (eg sucked up through a pipe) at the same temperature as the tank; there it is subjected to ultrasound so that crystals are formed; it is then transferred back into the tank. If no crystals are formed, this operation may be repeated.
Claims (5)
- 2. A method as claimed in claim 1 wherein the ultrasound is provided to the supersaturated solution in a vessel using a multiplicity of ultrasonic transducers attached to a wall of the vessel in an array extending both circumferentially and longitudinally, each transducer being connected to a signal generator so that the transducer radiates no more than 3 W/cm 2 the transducers being sufficiently close together and the number of transducers being sufficiently high that the power dissipation within the vessel is between 25 and 150 W/litre.
- 3. A method as claimed in any one of the preceding claims wherein ultrasound is applied in such a way that no focusing of the ultrasound occurs.
- 4. A method as claimed in claim 4 wherein focusing is prevented by energising groups of adjacent transducers in 11 \O IND succession. O 5. A method as claimed in claim 3 or claim 4 wherein Z focusing is prevented by energising adjacent transducers, or adjacent groups of transducers, at different frequencies. \O
- 6. A method as claimed in any one of the preceding claims wherein the crystalline material is aspartame. C(
- 7. A method as claimed in any one of claims 1 to Swherein the crystalline material is an amino acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212626.6A GB0212626D0 (en) | 2002-05-31 | 2002-05-31 | Production of crystalline ingredients |
| GB0212626.6 | 2002-05-31 | ||
| PCT/GB2003/001905 WO2003101577A1 (en) | 2002-05-31 | 2003-05-08 | Production of crystalline materials by using high intensity ultrasound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003229976A1 AU2003229976A1 (en) | 2003-12-19 |
| AU2003229976B2 true AU2003229976B2 (en) | 2008-11-13 |
Family
ID=9937808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003229976A Ceased AU2003229976B2 (en) | 2002-05-31 | 2003-05-08 | Production of crystalline materials by using high intensity ultrasound |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1509300B2 (en) |
| JP (1) | JP4336644B2 (en) |
| CN (1) | CN100354019C (en) |
| AT (1) | ATE342111T1 (en) |
| AU (1) | AU2003229976B2 (en) |
| BR (1) | BR0309908A (en) |
| CA (1) | CA2485199A1 (en) |
| DE (1) | DE60309023T3 (en) |
| DK (1) | DK1509300T4 (en) |
| ES (1) | ES2275091T5 (en) |
| GB (1) | GB0212626D0 (en) |
| MX (1) | MXPA04011911A (en) |
| NO (1) | NO20045575L (en) |
| NZ (1) | NZ536416A (en) |
| OA (1) | OA12822A (en) |
| PT (1) | PT1509300E (en) |
| WO (1) | WO2003101577A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503193D0 (en) * | 2005-02-16 | 2005-03-23 | Accentus Plc | Ultrasonic treatment plant |
| WO2009041385A1 (en) * | 2007-09-27 | 2009-04-02 | Ajinomoto Co., Inc. | PROCESS FOR PRODUCTION OF α-TYPE GLUTAMIC ACID CRYSTAL |
| FR2929040B1 (en) * | 2008-03-18 | 2010-04-23 | Super Sonic Imagine | INSONIFYING DEVICE HAVING AN INTERNAL COOLING CHAMBER |
| CA2729644C (en) | 2008-07-18 | 2018-05-29 | Prosonix Limited | Process for improving crystallinity |
| GB0821419D0 (en) | 2008-11-24 | 2008-12-31 | Bio Sep Ltd | Processing of biomass |
| GB0900080D0 (en) * | 2009-01-06 | 2009-02-11 | Prosonix Ltd | An apparatus and process for producing crystals |
| GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
| US20140031557A1 (en) * | 2011-04-18 | 2014-01-30 | Hefeibeinie Medical Technology Company, Ltd. | Method for purification of calcium channel blockers of dihydorpyridine type and preparation of nanoparticles thereof |
| GB201303520D0 (en) | 2013-02-27 | 2013-04-10 | Bio Sep Ltd | Biomass process optimisation |
| GB201303521D0 (en) | 2013-02-27 | 2013-04-10 | Bio Sep Ltd | Process operations for biomass fractionation |
| US9855538B2 (en) | 2013-03-08 | 2018-01-02 | The Board Of Trustees Of The University Of Illinois | Ultrasonic method and apparatus for producing particles having a controlled size distribution |
| GB2548117B (en) * | 2016-03-08 | 2022-10-26 | Lewtas Science & Tech Ltd | Use of ultrasound and acoustics to control crystallisation |
| CN107008028B (en) * | 2017-05-22 | 2023-09-08 | 天津晶润锐拓科技发展有限公司 | Crystallizer for controlling crystallization and nucleation process through ultrasonic waves |
| CN110354528B (en) * | 2019-08-21 | 2021-11-19 | 贺剑 | Solution crystallization system and method for promoting crystallization of solution |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035579A1 (en) * | 1998-12-12 | 2000-06-22 | Aea Technology Plc | Process and apparatus for irradiating fluids |
| WO2000079095A1 (en) * | 1999-06-22 | 2000-12-28 | Bp Exploration Operating Company Limited | Reduction in mineral salt deposition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828721D0 (en) * | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
| DE10123073A1 (en) * | 2001-05-11 | 2003-03-27 | Fraunhofer Ges Forschung | Process for the production of crystals from solids dissolved in a solvent |
-
2002
- 2002-05-31 GB GBGB0212626.6A patent/GB0212626D0/en not_active Ceased
-
2003
- 2003-05-08 BR BR0309908-3A patent/BR0309908A/en not_active Application Discontinuation
- 2003-05-08 DK DK03722816.0T patent/DK1509300T4/en active
- 2003-05-08 PT PT03722816T patent/PT1509300E/en unknown
- 2003-05-08 CA CA002485199A patent/CA2485199A1/en not_active Abandoned
- 2003-05-08 CN CNB038123649A patent/CN100354019C/en not_active Expired - Fee Related
- 2003-05-08 WO PCT/GB2003/001905 patent/WO2003101577A1/en not_active Ceased
- 2003-05-08 MX MXPA04011911A patent/MXPA04011911A/en active IP Right Grant
- 2003-05-08 NZ NZ536416A patent/NZ536416A/en unknown
- 2003-05-08 AT AT03722816T patent/ATE342111T1/en active
- 2003-05-08 OA OA1200400312A patent/OA12822A/en unknown
- 2003-05-08 DE DE60309023T patent/DE60309023T3/en not_active Expired - Lifetime
- 2003-05-08 JP JP2004508924A patent/JP4336644B2/en not_active Expired - Fee Related
- 2003-05-08 ES ES03722816T patent/ES2275091T5/en not_active Expired - Lifetime
- 2003-05-08 EP EP03722816A patent/EP1509300B2/en not_active Expired - Lifetime
- 2003-05-08 AU AU2003229976A patent/AU2003229976B2/en not_active Ceased
-
2004
- 2004-12-21 NO NO20045575A patent/NO20045575L/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035579A1 (en) * | 1998-12-12 | 2000-06-22 | Aea Technology Plc | Process and apparatus for irradiating fluids |
| WO2000079095A1 (en) * | 1999-06-22 | 2000-12-28 | Bp Exploration Operating Company Limited | Reduction in mineral salt deposition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100354019C (en) | 2007-12-12 |
| JP4336644B2 (en) | 2009-09-30 |
| BR0309908A (en) | 2005-02-09 |
| CA2485199A1 (en) | 2003-12-11 |
| NZ536416A (en) | 2006-09-29 |
| EP1509300B2 (en) | 2010-02-24 |
| DE60309023T3 (en) | 2010-09-09 |
| OA12822A (en) | 2006-07-10 |
| ATE342111T1 (en) | 2006-11-15 |
| GB0212626D0 (en) | 2002-07-10 |
| ES2275091T3 (en) | 2007-06-01 |
| MXPA04011911A (en) | 2005-03-31 |
| WO2003101577A1 (en) | 2003-12-11 |
| JP2005527367A (en) | 2005-09-15 |
| DE60309023T2 (en) | 2007-03-08 |
| DE60309023D1 (en) | 2006-11-23 |
| AU2003229976A1 (en) | 2003-12-19 |
| PT1509300E (en) | 2007-01-31 |
| DK1509300T4 (en) | 2010-06-14 |
| EP1509300B1 (en) | 2006-10-11 |
| CN1726069A (en) | 2006-01-25 |
| ES2275091T5 (en) | 2010-06-02 |
| NO20045575L (en) | 2004-12-21 |
| EP1509300A1 (en) | 2005-03-02 |
| DK1509300T3 (en) | 2006-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2485941C (en) | Production of crystalline materials by using high intensity ultrasound | |
| AU2003229976B2 (en) | Production of crystalline materials by using high intensity ultrasound | |
| US7128784B2 (en) | Small particle-adjustment crystallization process | |
| US12268995B2 (en) | Use of ultrasound and acoustics to control crystallisation | |
| US7244307B2 (en) | Production of crystalline materials by using high intensity ultrasound | |
| US20030166726A1 (en) | Crystallization of amino acids using ultrasonic agitation | |
| AU2005219639B2 (en) | Removal of sodium oxalate from a Bayer liquor | |
| IL164854A (en) | Production of crystalline materials by using high intensity ultrasound | |
| KR20050016476A (en) | Production of crystalline materials by using high intensity ultrasound | |
| KR20050016436A (en) | Production of crystalline materials by using high intensity ultrasound | |
| Narducci | Particle Engineering via Sonocrystallization: the aqueous adipic acid system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |